FDA

"new" alliance- Just FYI

  The Food and Drug Administration (FDA) invites you to partner with and become a member of the Global Alliance of Drug Information Specialists (GADIS).  We recognize your contributions in clinical practice and request your ...

Antidepressant induced EPS

Does anyone by chance have any information regarding comparisons between antidepressants in inducing EPS?   Christopher Ching, PharmD Inpatient Pharmacist Kaiser Permanente Behavioral Health Center 3840 Homestead Rd. Santa Clara, CA 95051 ...

Quetiapine IR

Dear List mates,   Does anyone know who will be coming out with a generic Quetiapine IR?     Best Regards,   Navindra Ramcharran, PharmD, RPh, MSBFSM email: nramcharran@imscg.com

Podcast: Changing FDA Recommendations on Citalopram. . Why Now?

Have you heard the news that citalopram should no longer be used at doses greater than 40 mg? Steven Moffic, MD, explores the issues surrounding this recent recommendation.

Lack of investment in regulatory science is part of "innovation gap," believes FDA commissioner

Margaret Hamburg, the commissioner of the US Food and Drug Administration, believes that a failure to invest “adequately” in regulatory science has been one of the reasons why fewer new drugs have...

Viibryd (Vilazodone): Viable Option or For the Byrds?

Misty L. Gonzalez, PharmD, BCPP
Clinical Assistant Professor, Department of Pharmacy Practice
Southern Illinois University Edwardsville (SIUE)
School of Pharmacy

SB is a 25 year-old patient with General Anxiety Disorder and Major Depressive Disorder who arrives to your medication management clinic. She has a previous history of fluoxetine and duloxetine use, which she did not tolerate well. She is currently taking sertraline 150 mg daily and says the effect is wearing-off and that she would like to try something different. Her psychiatrist is considering augmentation, but is concerned about pill-burden. Are there any newer antidepressant treatment options for SB that may help provide better symptom control?    

New Drug Review- Ezogabine (Potiga): Seizing the Seizure

Misty L. Gonzalez, PharmD, BCPP
Clinical Assistant Professor, Department of Pharmacy Practice
Southern Illinois University Edwardsville (SIUE)
School of Pharmacy

JR is a 33 year-old patient with complex partial seizures with secondary generalization who arrives to your medication management clinic. He has a significant history of anticonvulsant use and polytherapy, to which he has not responded optimally. JR is currently taking divalproex 1250 mg twice daily and topiramate 200 mg twice daily and continues to have monthly seizure episodes. He is highly motivated to become seizure-free. His neurologist is considering augmentation, but requests your expertise for an adjunctive agent.

New Drug Review: Gabapentin enacarbil extended release (Horizant™) – A New Formulation on the Horizon

Amy B. Werremeyer, PharmD, BCPP
Assistant Professor, Department of Pharmacy Practice
North Dakota State University
College of Pharmacy, Nursing and Allied Sciences

GR is a 57-year-old female who is not sleeping well due to her Restless Legs Syndrome.  She reports strong, irresistible urges to move her legs when she is watching TV at night, and these worsen when she lies in bed and tries to fall asleep. She currently takes ropinirole 4mg PO 2 hours before bedtime with some improvement in her symptoms, but she would like an even greater benefit from her medication. She has taken levodopa/carbidopa in the past for her restless legs, but she reported that the symptoms were occurring earlier in the day and were migrating into her arms while she was on it. GR would like to know if there are any additional treatments for her restless legs that may offer additional symptom relief.

Gabapentin enacarbil structure

This page may contain content contributed by CPNP members or aggregated from other online sources. This content is provided as an unmoderated service to members for civil discussion and collaboration. Any opinions, conclusions, or recommendations are those of the author. If you come across any abuse or violation of the terms of use, please report the abuse.